0.66
+0.0582(+9.75%)
Currency In USD
| Previous Close | 0.6 |
| Open | 0.6 |
| Day High | 0.66 |
| Day Low | 0.6 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.16 |
| Volume | 9.07M |
| Average Volume | 18.91M |
| Market Cap | 39.62M |
| PE | -0.68 |
| EPS | -0.96 |
| Moving Average 50 Days | 0.6 |
| Moving Average 200 Days | 0.6 |
| Change | 0.06 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.02 as of December 04, 2025 at a share price of $0.655. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $20.6 as of December 04, 2025 at a share price of $0.655.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
GlobeNewswire Inc.
10 hours ago
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated promising safety and efficacy signal,
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 01, 2025 12:30 PM GMT
Study findings to be featured in a poster spotlight presentationHOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with ad
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
GlobeNewswire Inc.
Nov 24, 2025 12:30 PM GMT
HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announce